Ignite Creation Date:
2024-05-05 @ 4:57 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00350051
Status:
COMPLETED
Last Update Posted:
2021-04-08
First Post:
2006-07-07
Brief Title:
ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent Prostate Cancer
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
Phase 2 Study of ZK-Epothilone ZK-Epo ZK219477 Plus Prednisone as First-line Chemotherapy in Patients With Metastatic Androgen-independent Prostate Cancer
Status:
COMPLETED
Status Verified Date:
2021-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate whether treatment with a new drug called ZK-Epothilone ZK-Epo given with prednisone in patients with androgen-independent prostate cancer who have not had previous chemotherapy is safe and helps to decrease PSA Prostate-specific antigen levels
Detailed Description:
This study has previously been posted by Berlex Inc and Schering AG GermanyBerlex Inc has been renamed to Bayer HealthCare Pharmaceuticals Inc Schering AG Germany has been renamed to Bayer Schering Pharma AG Germany Bayer HealthCare Pharmaceuticals Incand Bayer Schering Pharma AG Germany are the sponsors of the trial
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 307976 | OTHER | Company internal | None |